While the option of targeted therapy is available for patients with BRAF V600‐mutant melanoma, patients with melanomas of the RAS, NF1, or triple‐wild‐type subtypes usually have no efficient therapeutic option besides immunotherapy. This evidence concerns the gene BRAF and melanoma.